Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 10.63% is 3072% above its 5-year average of 0.34%, around the middle of its 5-year range (0.00%–29.24%).
As of the fiscal period ended Friday, July 31, 2026. 28.88% above its 12-month average of 8.25%.
Reported quarterly debt to assets ratio; no daily interpolation. Q3 FY2026 (2026-07-31): 10.63%.
DEBT TO ASSETS RATIO
10.63%
DEBT TO ASSETS RATIO AVG TTM
8.25%
DEBT TO ASSETS RATIO AVG 3Y
0.47%
DEBT TO ASSETS RATIO AVG 5Y
0.34%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+28.88%
CURRENT VS 3Y AVG
+2157.62%
CURRENT VS 5Y AVG
+3072.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 469 covered companies
CURRENT VS SECTOR MEDIAN
+9566.55%
vs the sector median at left
Clearmind Medicine Inc.
Market Cap
$1.11M
Debt to Assets Ratio
10.63%
TTM Avg
8.25%
3Y Avg
0.47%
5Y Avg
0.34%
Market Cap
$1.14M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$888387.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$885939.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$878396.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.36M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.11M | 10.63% | 8.25% | 0.47% | 0.34% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | 0.10% | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | 0.56% | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | 0.00% | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | 0.00% | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | 0.01% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | 0.00% | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | 0.01% | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.37M | 0.00% | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | 0.01% | N/A | N/A | N/A |
Debt/Assets
10.6%
Debt/Equity
0.14
Current Ratio
4.31
Interest Coverage
-290.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-07-31 | 10.63% |
| 2026-04-30 | 0.59% |
| 2026-01-31 | 0.07% |
| 2025-10-31 | 29.24% |
| 2025-07-31 | 0.72% |
| 2025-04-30 | 0.69% |
| 2025-01-31 | 0.70% |
| 2024-10-31 | 0.73% |
| 2024-07-31 | 0.75% |
| 2024-04-30 | 0.00% |
| 2024-01-31 | 0.93% |
| 2023-10-31 | 0.00% |
| 2023-07-31 | 0.00% |
| 2023-04-30 | 0.08% |
| 2023-01-31 | 0.43% |
| 2022-10-31 | 4.65% |
| 2022-07-31 | 4.24% |
| 2022-04-30 | 0.00% |
| 2022-01-31 | 0.00% |
| 2021-10-31 | 0.00% |
| 2021-07-31 | 0.00% |
| 2021-04-30 | 0.00% |
| 2021-01-31 | 0.00% |
| 2020-10-31 | 0.00% |
| 2020-07-31 | 0.00% |
| 2020-04-30 | 0.00% |
| 2020-01-31 | 0.00% |
| 2019-10-31 | 0.00% |
| 2019-07-31 | 0.00% |
| 2019-04-30 | 0.00% |
| 2019-01-31 | 0.00% |
| 2018-10-31 | 0.00% |
| 2018-07-31 | 0.00% |
| 2018-04-30 | 0.00% |
| 2018-01-31 | 0.00% |
